




ASO VISUAL ABSTRACT


## ASO Visual Abstract: Neoadjuvant Chemotherapy and Endoprosthetic Reconstruction for Lower-Extremity Sarcomas—Does Timing Impact Complication Rates?

Aaron M. Gazendam, MD<sup>2</sup> , Patricia Schneider, BSc<sup>2</sup>, Andre Spiguel, MD, FAAOS<sup>3</sup>, Michelle Ghert, MD, FRCSC<sup>2</sup> on behalf of the PARITY Investigators<sup>1</sup>

<sup>1</sup>Investigation performed at McMaster University, Hamilton, Canada; <sup>2</sup>Division of Orthopaedic Surgery, McMaster University, Hamilton, Ontario, Canada; <sup>3</sup>Department of Orthopaedics and Rehabilitation, University of Florida College of Medicine, Gainesville, FL

Timing of surgery following neoadjuvant chemotherapy varies considerably in patients with sarcoma undergoing lower-extremity endoprosthetic reconstruction . Timing of

surgery did not impact infection or reoperation rates in this cohort (<https://doi.org/10.1245/s10434-022-12258-w>).



**FUNDING** The PARITY trial received funding through research grants from the Canadian Institutes of Health Research (CIHR), the Canadian Cancer Society Research Institute, the Canadian Orthopaedic Foundation, the Orthopaedic Research and Education Foundation in conjunction with the Musculoskeletal Tumor Society, and the Physicians' Services Incorporated research grant. M.G. reports speaker fees from Stryker.

**DISCLOSURE** All other authors declare no conflicts of interest.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.